These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 16964289

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The oncogenic potential of the Pax3-FKHR fusion protein requires the Pax3 homeodomain recognition helix but not the Pax3 paired-box DNA binding domain.
    Lam PY, Sublett JE, Hollenbach AD, Roussel MF.
    Mol Cell Biol; 1999 Jan; 19(1):594-601. PubMed ID: 9858583
    [Abstract] [Full Text] [Related]

  • 4. PAX3/forkhead homolog in rhabdomyosarcoma oncoprotein activates glucose transporter 4 gene expression in vivo and in vitro.
    Armoni M, Quon MJ, Maor G, Avigad S, Shapiro DN, Harel C, Esposito D, Goshen Y, Yaniv I, Karnieli E.
    J Clin Endocrinol Metab; 2002 Nov; 87(11):5312-24. PubMed ID: 12414908
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene.
    Khan J, Bittner ML, Saal LH, Teichmann U, Azorsa DO, Gooden GC, Pavan WJ, Trent JM, Meltzer PS.
    Proc Natl Acad Sci U S A; 1999 Nov 09; 96(23):13264-9. PubMed ID: 10557309
    [Abstract] [Full Text] [Related]

  • 8. Tumor-specific PAX3-FKHR transcription factor, but not PAX3, activates the platelet-derived growth factor alpha receptor.
    Epstein JA, Song B, Lakkis M, Wang C.
    Mol Cell Biol; 1998 Jul 09; 18(7):4118-30. PubMed ID: 9632796
    [Abstract] [Full Text] [Related]

  • 9. Wild type PAX3 protein and the PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma contain potent, structurally distinct transcriptional activation domains.
    Bennicelli JL, Fredericks WJ, Wilson RB, Rauscher FJ, Barr FG.
    Oncogene; 1995 Jul 06; 11(1):119-30. PubMed ID: 7624119
    [Abstract] [Full Text] [Related]

  • 10. The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3.
    Fredericks WJ, Galili N, Mukhopadhyay S, Rovera G, Bennicelli J, Barr FG, Rauscher FJ.
    Mol Cell Biol; 1995 Mar 06; 15(3):1522-35. PubMed ID: 7862145
    [Abstract] [Full Text] [Related]

  • 11. Transgenic mice expressing PAX3-FKHR have multiple defects in muscle development, including ectopic skeletal myogenesis in the developing neural tube.
    Finckenstein FG, Davicioni E, Osborn KG, Cavenee WK, Arden KC, Anderson MJ.
    Transgenic Res; 2006 Oct 06; 15(5):595-614. PubMed ID: 16952014
    [Abstract] [Full Text] [Related]

  • 12. Analysis of genetic events that modulate the oncogenic and growth suppressive activities of the PAX3-FKHR fusion oncoprotein.
    Xia SJ, Rajput P, Strzelecki DM, Barr FG.
    Lab Invest; 2007 Apr 06; 87(4):318-25. PubMed ID: 17297479
    [Abstract] [Full Text] [Related]

  • 13. The alveolar rhabdomyosarcoma PAX3/FKHR fusion protein is a transcriptional activator.
    Sublett JE, Jeon IS, Shapiro DN.
    Oncogene; 1995 Aug 03; 11(3):545-52. PubMed ID: 7630639
    [Abstract] [Full Text] [Related]

  • 14. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma.
    Barr FG.
    Oncogene; 2001 Sep 10; 20(40):5736-46. PubMed ID: 11607823
    [Abstract] [Full Text] [Related]

  • 15. Co-expression of alternatively spliced forms of PAX3, PAX7, PAX3-FKHR and PAX7-FKHR with distinct DNA binding and transactivation properties in rhabdomyosarcoma.
    Du S, Lawrence EJ, Strzelecki D, Rajput P, Xia SJ, Gottesman DM, Barr FG.
    Int J Cancer; 2005 May 20; 115(1):85-92. PubMed ID: 15688409
    [Abstract] [Full Text] [Related]

  • 16. Analysis of the transforming and growth suppressive activities of the PAX3-FKHR oncoprotein.
    Xia SJ, Barr FG.
    Oncogene; 2004 Sep 09; 23(41):6864-71. PubMed ID: 15286710
    [Abstract] [Full Text] [Related]

  • 17. An engineered PAX3-KRAB transcriptional repressor inhibits the malignant phenotype of alveolar rhabdomyosarcoma cells harboring the endogenous PAX3-FKHR oncogene.
    Fredericks WJ, Ayyanathan K, Herlyn M, Friedman JR, Rauscher FJ.
    Mol Cell Biol; 2000 Jul 09; 20(14):5019-31. PubMed ID: 10866659
    [Abstract] [Full Text] [Related]

  • 18. The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence.
    Linardic CM, Naini S, Herndon JE, Kesserwan C, Qualman SJ, Counter CM.
    Cancer Res; 2007 Jul 15; 67(14):6691-9. PubMed ID: 17638879
    [Abstract] [Full Text] [Related]

  • 19. PAX3 and PAX7 exhibit conserved cis-acting transcription repression domains and utilize a common gain of function mechanism in alveolar rhabdomyosarcoma.
    Bennicelli JL, Advani S, Schäfer BW, Barr FG.
    Oncogene; 1999 Jul 29; 18(30):4348-56. PubMed ID: 10439042
    [Abstract] [Full Text] [Related]

  • 20. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.
    Taulli R, Scuoppo C, Bersani F, Accornero P, Forni PE, Miretti S, Grinza A, Allegra P, Schmitt-Ney M, Crepaldi T, Ponzetto C.
    Cancer Res; 2006 May 01; 66(9):4742-9. PubMed ID: 16651427
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.